Generated by AI
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on developing, producing, and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. The company’s current portfolio centers on treatments for rare diseases, including Elelyso for Gaucher disease and Elfabrio for adult patients with Fabry disease. Protalix also advances a pipeline of plant cell-expressed candidates such as PRX-115 for gout and PRX-119 for NETs-related diseases, reflecting its emphasis on enzyme replacement therapies and other biologic approaches for conditions with limited treatment options. Based in Karmiel, Israel, Protalix serves global markets through product commercialization and partnership-based development across its specialty biopharmaceutical programs.
Website2 University Plaza
Hackensack, NJ, 07601
United States
The latest articles about PLX.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 11's posts. Generated by AI.
(AP) — Protalix BioTherapeutics Inc. (PLX) on Tuesday reported profit of $4 million in its third quarter.
Summary of Feb 2's posts. Generated by AI.
Investors talking about PLX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.